Less than half of 300 doctors polled in a QuantiaMD survey could name a biosimilar that’s under consideration for approval, and only 17% said they’re very likely to prescribe one.
Five things for pharma marketers to know: Wednesday, July 22
Experimental Alzheimer’s disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed
The health insurance industry’s trade association, along with other organizations, sent a letter to the FDA arguing that different names could lead to prescriber confusion and medication errors.
Five things for pharma marketers to know: Wednesday, June 10
FDA panel recommends Sanofi/Regeneron’s PCSK9 inhibitor for approval; Merck and Samsung collaboration says their rheumatoid arthritis biosimilars are equivalent to the biologic versions; Bayer offloads its diabetes-care business
Five things for pharma marketers to know, Thursday, June 4
An economist wants $37 billion invested in antibiotic development; Roche plans to file an experimental lung-cancer drug with the FDA this year; Sandoz wants compensation for lost Zarxio sales
Five things for pharma marketers to know: Thursday, May 7
A court halted the launch of Sandoz’s biosimilar; GSK said it is concerned about Advair competition in the US; an FDA panel is expected to vote on a female sexual disorder drug
Five things for pharma marketers to know: Friday, May 1
Nexium tops the list of Medicare’s spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company